https://altg.com.au/members-area/mac-and-sac-meeting-november-2018/

Welcome to ALTG

New ALTG Study ILLUMINATE:
Feasibility is open for the ILLUMINATE Study (ALTG 16/009) which is a phase 2 trial of durvalumab and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on epidermal growth factor receptor (EGFR) mutation Tyrosine Kinase Inhibitors (TKIs).

ALTG Speaking Tour:
The purpose of this educational evening is to provide practical evidence-based strategies for use within the multidisciplinary team environment but also to identify potential gaps in research.

For Patients

Upcoming Events

Upcoming Events
  1. 2018 ALTG Speaking Tour – Melbourne evening

    October 2 @ 6:00 pm - 9:00 pm
  2. 2018 ALTG Speaking Tour – Brisbane evening

    October 4 @ 6:00 pm - 9:00 pm
  3. ALTG Members Meeting

    October 5 @ 1:00 pm - 5:00 pm
  4. ALTG Symposium 2018

    October 6 @ 8:30 am - 4:00 pm
  5. Management Advisory Committee (MAC) Meeting

    November 23